{
  "id": 8898262,
  "title": "Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial",
  "url": "https://urgent.news/2026/09/21/cue-biopharmas-potential-xolair-challenger-passes-phase-2-chronic",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-21T10:17:43.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/cue-biopharmas-potential-xolair-challenger-passes-phase-2-chronic-hives-trial/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Cue Biopharma said Sunday its chronic hives candidate cleared a mid-stage trial, marking its first clinical data since its strategic pivot from cancer into immunology. In a Phase 2 China study in chronic spontaneous urticaria ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Cue Biopharma reports positive phase 2 results for CUE-221",
        "url": "https://urgent.news/2026/09/20/cue-biopharma-reports-positive-phase-2-results-for-cue-221",
        "published": "2026-09-20T10:04:46.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}